Introduction

The fixed combination of saxagliptin and metformin (trade name: Komboglyze) has been approved in Germany since November 2011 for the treatment of type 2 diabetes in adults who can't lower high blood sugar levels enough through exercise and diet alone. The combination can also be used together with other blood-sugar-lowering drugs.

Diabetes is a metabolic disease that affects many parts of the body. In type 2 diabetes, the pancreas still produces enough insulin at first, but the body’s cells gradually lose the ability to absorb and use the insulin. If blood sugar levels can't be lowered enough through a change in diet and exercise habits, blood-sugar-lowering medication is used.

The aim of treatment for type 2 diabetes is to avoid strong fluctuations in blood sugar levels and the effects of high and low blood sugar. A further goal of this treatment is to prevent long-term complications that may arise if blood sugar levels are too high.

Application

Saxagliptin / metformin is taken twice daily as a tablet with meals. One tablet contains 2.5 mg of saxagliptin and either 850 mg or 1000 mg of metformin, depending on how high the previous dose of metformin was.

Other treatments

Type 2 diabetes can be treated with a number of different medicines, either as monotherapy or in combination with each other. These medicines include metformin, empagliflozin, liraglutide, sulfonylurea and insulin.

Assessment

The Institute for Quality and Efficiency in Health Care (IQWiG, Germany) last looked into whether the fixed combination of saxagliptin and metformin has advantages or disadvantages compared to the standard treatments in 2017.

But the manufacturer didn’t provide any suitable data with which to do the assessment.

More information

This information summarizes the main results of reviews produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The reviews were commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the reviews and the hearings received, the G-BA passed a resolution on the added benefit of saxagliptin / metformin (Komboglyze).